Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.
Department of Surgery, Yokohama City University, Yokohama, Japan.
Anticancer Res. 2023 Apr;43(4):1689-1697. doi: 10.21873/anticanres.16321.
BACKGROUND/AIM: Trifluridine/tipiracil (FTD/TPI) is an anticancer-agent that is administered as third-line or later chemotherapy for metastatic gastric/gastroesophageal junction cancer (mGC/GEJC). Although inflammatory and nutritional statuses have attracted attention as prognostic factors for patients with mGC/GEJC in this therapy, their usefulness has not been fully clarified. Thus, this study investigated the clinical significance of prognostic nutritional index (PNI), neutrophil/lymphocyte ratio (NLR), and NLR/serum albumin (Alb) ratio in patients administered FTD/TPI.
This retrospective study included 64 patients who underwent FTD/TPI treatment for mGC/GEJC at Kanagawa Cancer Center, Kanagawa, Japan, between October 2019 and June 2022. Patients were divided into high and low PNI, NLR, and NLR/Alb groups according to their pretreatment blood data. This study evaluated the associations between the inflammatory and nutritional indexes and survivals.
Overall survival (OS) and progression-free survival (PFS) of patients with low PNI were significantly poorer than those with high PNI. However, low PNI was not an independent prognostic factor for OS and PFS. There was no significant association between NLR and OS or PFS. In contrast, the OS of patients with high NLR/Alb was significantly poorer than those with high PNI and low NLR/Alb. Furthermore, multivariate analysis showed that high NLR/Alb was an independent prognostic factor for OS.
The NLR/Alb may be a useful prognostic factor in patients with mGC/GEJC being administered FTD/TPI as third-line or later chemotherapy.
背景/目的:替氟尿苷/盐酸拓扑替康(FTD/TPI)是一种抗癌药物,作为转移性胃癌/胃食管结合部癌(mGC/GEJC)的三线或三线以上化疗药物。尽管在这种治疗中,炎症和营养状况作为 mGC/GEJC 患者的预后因素已经引起了关注,但它们的有用性尚未得到充分阐明。因此,本研究调查了预后营养指数(PNI)、中性粒细胞/淋巴细胞比值(NLR)和 NLR/血清白蛋白(Alb)比值在接受 FTD/TPI 治疗的患者中的临床意义。
本回顾性研究纳入了 2019 年 10 月至 2022 年 6 月在日本神奈川癌症中心接受 FTD/TPI 治疗的 64 例 mGC/GEJC 患者。根据治疗前的血液数据,患者被分为高和低 PNI、NLR 和 NLR/Alb 组。本研究评估了炎症和营养指标与生存之间的关系。
低 PNI 患者的总生存期(OS)和无进展生存期(PFS)明显较差,但低 PNI 不是 OS 和 PFS 的独立预后因素。NLR 与 OS 或 PFS 之间无显著相关性。相比之下,高 NLR/Alb 患者的 OS 明显差于高 PNI 和低 NLR/Alb 患者。此外,多变量分析显示高 NLR/Alb 是 OS 的独立预后因素。
在接受 FTD/TPI 作为三线或三线以上化疗的 mGC/GEJC 患者中,NLR/Alb 可能是一个有用的预后因素。